

ASX Code: GSS
22 March 2019

Change in Director's Interest Notice

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) advises that Non-Executive Director, Dr Anthony Radford, has sold 107,000 shares in GSS to fund expected tax obligations triggered from the release of shares held in escrow.

Post the sale, Dr Radford still retains 240,000 shares.

The sale was conducted in accordance with the Company's Share Trading Policy.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Chief Executive Officer
john@geneticsignatures.com

Peter Manley
Chief Financial Officer
peter.manley@geneticsignatures.com

T: +61 (0)2 9870 7580

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx **3base**[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENETIC SIGNATURES LIMITED
ABN	30 095 913 205

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Anthony (Tony) Radford
Date of last notice	24 October 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Koona Nominees Pty Ltd (Trustee of the self managed super fund of which Tony Radford is a director)
Date of change	-	15 & 18 March 2019
No. of securities held prior to change	240,000	107,000
Class	170,00 FPO shares 70,000 GSS Employee Share Plan (ESP) shares	FPO shares
Number acquired	Nil	Nil
Number disposed	Nil	107,000
Value/Consideration <input type="checkbox"/> Note: If consideration is non-cash, provide details and estimated valuation <input type="checkbox"/>	-	\$124,053.30

+ See chapter 19 for defined terms.

No. of securities held after change	240,000	Nil
Nature of change <input type="checkbox"/> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	N/a	On market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration <input type="checkbox"/> Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

⁺ See chapter 19 for defined terms.